The abstract is read at the publisher; the summary is JClub's.
In a randomized trial of transfemoral TAVR in China, single-ProGlide closure was noninferior to double-ProGlide for VARC-3 access-site or access-related vascular complications (13.1% vs 15.1%).
- Why it matters: Access-site vascular complications after TAVR remain a key source of morbidity, and the conventional double-ProGlide approach may be riskier in patients with challenging iliofemoral anatomy.
- What they did: In a prospective, multicenter, open-label trial at 25 centers, 876 patients aged ≥65 years were randomized 1:1 to single- vs double-ProGlide, with a VARC-3-defined in-hospital composite as the primary endpoint.
- The result: The primary endpoint occurred in 57/436 (13.1%) vs 65/430 (15.1%), meeting noninferiority (risk difference -2.2%, 95% -7.0% to 2.6%, P=0.013), with similar bleeding, hemostasis time, and mortality.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.